Current position: Leader of Department of Urology, Luohu Hospital Group, Shenzhen, Secretary of Party Committee of Shenzhen Luohu Hospital Group, Director of Institute of Urology, Shenzhen University, Director of Shenzhen Urological Surgery Quality Control Center

Hosted the project: 1 national key research and development plan, 2 National Natural Science Fund

Social position: Now a member of the International Tumor Genome Synergy Group, a member of the Chinese Medical Association Urology Branch, a member of the Urology Branch of the Guangdong Medical Association, a vice president of the Guangdong Urological Association, and a precision medicine and molecular diagnostic branch of the Guangdong Medical Association. Deputy Director, President of Precision Medicine Branch of Shenzhen Medical Association.

Research areas:

Early diagnosis and treatment of tumors

Email：wusong@szu.edu.cn

Awards:

1. 2019 Guangdong Provincial Party Committee Organization Department and Science and Technology Department leading talents in science and technology innovation

2. Guangdong Province Medical Leaders in 2018

3. In 2017, won the second prize of the Outstanding Achievement Award of the Ministry of Education (2/15)

4. Third Prize of China Medical Science and Technology Award in 2016 (1/15)

5. In 2016, won the National May 1st Labor Medal (1/1)

6. In 2016, Forbes 30 30-year-old Asian healthcare professionals in the field of health (1/1)

7. Received the first prize of the Natural Science of Guangdong Province in 2016 (10/15)

8. In 2015, won the Guangdong Provincial Special Support Program, Science and Technology Innovation, Young Talents

9. Received the Shenzhen Youth Science and Technology Award in 2015 (1/1)

Academic Works:

1) Guo G#, Sun X#, Chen C#, Wu S#, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, Song P, Zhao X, Ye R , Zhang S, Lin Z, Qi M, Wan S, Xie L, Fan F, Nickerson ML, Zou X, Hu X, Xing L, Lv Z, Mei H, Gao S, Liang C, Gao Z, Lu J, Yu Y, Liu C, Li L, Fang X, Jiang Z, Yang J, Li C, Zhao X, Chen J, Zhang F, Lai Y, Lin Z, Zhou F, Chen H, Chan HC, Tsang S, Theodorescu D, Li Y, Zhang X, Wang J, Yang H, Gui Y*, Wang J*, Cai Z*. Whole-genome and whole-exome sequencing of bladder cancer identification frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013 Dec;45(12):1459-63. (Common first author) IF=31.616

2) Wu S#, Ou T#, Xing N#, Lu J, Wan S, Wang C, Zhang X, Yang F, Huang Y, Cai Z*. Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis- Related drivers in bladder cancer. [J]. Nat Com. 2019 Feb; 10(1):720. (Common first author, Corresponding author)

3) Yang Z#, Li C#, Fan Z#, Liu H#, Zhang X#, Cai Z#, Xu L, Luo J, Huang Y, He L, Liu C, Wu S*. Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells. [J]. Eur Urol, 2016. (Corresponding author) IF=17.581

4) Wu S*#, Huang P#, Li C#, Huang Y#, Li X#, Wang Y, Chen C, Lv Z, Tang A, Sun X, Lu J, Li W, Zhou J, Gui Y, Zhou F , Wang D, Cai Z*. Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular Study. Eur Urol. 2014 Feb;65(2): 274-7. (First author, co-communication Author) IF=17.581

5) Wu S#, Lv Z#, Zhu J#, Dong P, Zhou F, Li X, Cai Z*. Somatic Mutation of the Androgen Receptor Gene Is Not Associated with Transitional Cell Carcinoma: A “Negative” Study by Whole-exome Sequencing Analysis. Eur Urol. 2013 Dec;64(6):1018-9. (first author) IF= 17.581

6) Wu S#, Sun X#, Zhu W#, Huang Y#, Mou L#, Liu M, Li X, Li F, Li X, Zhang Y, Wang Z, Li W, Li Z, Tang A, Gui Y , Wang R, Li W, Cai Z*, Wang D*. Evidence for GAL3ST4 mutation as the potential cause of pectus excavatum. Cell Res. 2012;22(12):1712-1715. (first author) IF=15.393

7) Huang Y#, Gao S#, Wu S#*, Song P#, Sun X#, Hu X, Zhang S, Yu Y, Zhu J, Li C, Qin Z, Xie L, Yao Q, Tang A, Li Z, Guo G, Wan S, Dong P, Sun L, Li W, Wang D, Gui Y, Yang H, Zhou F, Zhang X, Cai Z*. Multilayered molecular profiling supported the monoclonal origin of metastatic renal cell carcinoma. Int J Cancer. 2013 Dec 6. doi: 10.1002/ijc.28654. (Common Corresponding author, co-first author) IF= 7.360